Moderna signs multi-year COVID-19 vaccine manufacturing agreement with National Resilience

Under the terms of a new, multi-year agreement reached this week between Moderna and National Resilience, National Resilience will produce mRNA for Moderna’s COVID-19 vaccines at its Mississauga, Ontario facility.

“Moderna’s COVID-19 vaccine has saved countless lives, and we’re excited to manufacture mRNA for this important vaccine,” Dr. Rahul Singhvi, CEO of National Resilience, said. “This collaboration has the potential to ensure more people are protected around the world from the deadly COVID-19 virus.”

The mRNA, produced in Canada, will go on to aid distribution worldwide. Along the way, the agreement also unites biopharmaceutical with biotechnology in the proliferation of pioneer mRNA medicines. Notably, that technology led to the creation of one of the earliest and most effective COVID-19 vaccines still in use.

Further aiding Moderna’s vaccine manufacturing efforts is a separate arrangement reached with the government of Canada this week, through a Memorandum of Understanding. That memorandum grants Moderna the rights to bring mRNA manufacturing into Canadian borders through a new manufacturing facility that will have access to Moderna’s mRNA development engine. In this way, Canada has moved to secure a measure of direct access to rapid pandemic response capabilities in general and Moderna’s developing vaccines in particular.